NEW ISSUE
EAPCI/ACVC consensus on pVADs, coronary physiology mini focus, a new analysis from the COAPT trial, patient selection for tricuspid interventions and more…
July 20, 2021
1. Department of Cardiology, University Hospital of Bern, Bern, Switzerland; 2. Interventional Cardiology, McGill University Health Centre, Montréal, Canada; 3. University of Paris, Paris, France; 4. Institut Cœur Poumon, Department of Cardiology and Cardiovascular Surgery, Heart Valve Center, CHU de Lille, Lille, France; 5. Jiao Tong University, Shanghai, China
Surgical treatment remains the cornerstone of valvular heart disease (VHD) treatment1. Surgery was the only option for all types of VHD until 1984 when the first report of transseptal percutaneous mitral balloon commissurotomy (PMC) in mitral rheumatic disease was published2,3. Shortly after followed the first report of balloon aortic valvuloplasty by Cribier and colleagues4. Some time later, first-in-man reports were successively published on transcatheter aortic valve implantation in 2002 and mitral edge-to-edge repair in 2004, followed more recently by mitral bioprosthetic replacement and tricuspid repair5,6,7,8. Nowadays, PMC is an established routine treatment for rheumatic mitral stenosis (more than 20 years of experience)9. With ...
Sign in to read and download the full article
Forgot your password?No account yet? Sign up for free!
Create my pcr account Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
Read next article
The five Ws of transcatheter mitral valve repair: Who, What, When, Where, and Why